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ABSTRACT 
Oral route is the most common preferred route. In market number of drugs are available with solubility problem. It is difficult to prefer oral 
conventional dosage form other drugs on this less solubility which result in loss bioavailability. Parenteral suspensions are dosage forms 
containing drugs having low solubility. Drugs in suspension form increase the solubility, stability of the drugs. Drugs in sulfonation form have 
large surfaces areas. Parenteral suspensions provides onset of action for prolonged line on compared to solution. 
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INTRODUCTION:[1-3] 
Parenteral preparations are defined as 
solutions, suspensions, emulsions for injection or infusion, 
powders for injection or infusion, gels for injection and 
implants. These are sterile preparations intended to be 
administrated directly into the systemic circulation in 
humans or animals. 
Parenteral suspensions are dispersed, heterogeneous 
systems containing insoluble drug particles which, when are 
to be resuspended in either aqueous or vegetable oil vehicles 
before giving it to the patient.They are either given by 
intramuscularly or subcutaneously. 
Ideal characteristics of parenteral suspensions: 
[2,5,6] 
 Sterility during its storage and use. 
 Injectability of suspensions are related to viscosity. 
 The size of the parenteral suspensions should be small 
and uniform. 
 Re-suspension of particles occurs very easily. 
 The particles which are dispersed and are not settled 
rapidly after shaking. 
 During shelf-life the cake formation does not occur. 
 The stability and elegance should be maintained during 
its shelf-life. 
 It is isotonic and non-irritating. 
 The particle size should be less than 5 mm and the solid 
should contain 0.5%-5.0%. 
 The suspensions that are manufactured should be 
tested for microbial contamination. 
Advantages of parenteral suspensions:[3] 
 The parenteral suspensions are insoluble in 
conventional solvents and are used therapeutically. 
 The dosage forms increases the resistance of the 
suspensions to hydrolysis and oxidation which are 
present in the form of solids. 
 The hepatic first pass effect is eliminated. 
 The formulation of controlled release drug is possible 
in this dosage form. 
Disadvantages of parenteral suspensions:[2-3] 
 Formulation difficulty: The suspending agents, 
viscosity inducing agents, wetting agents, stabilizers, 
and preservatives are difficult to select for this type of 
parenteral suspensions. 
 Manufacturing difficulty: The processes such as 
crystallization, particle size reduction, wetting, 
sterilization are facilitated which are required to 
maintain the aseptic conditions for manufacturing. 
 Non-uniformity of the dose at the time of 
administration. 
 The physical stability is very difficult to maintain in this 
dosage form. 
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Factors affecting release of drugs from parenteral 
suspension:[3,9] 
 At the injection site the drug is soluble in the form of 
biological fluids. 
 The drugs which are released can be affected by 
different steps involved in the process of suspensions. 
 The challenge to formulate an injectable suspension is 
accepted by parenteral. 
 These suspensions are usually diluted and are limited 
for viscosity because of injectability constraints and 
syringeability. 
 These suspensions use high solid contents and increase 
the viscosity of the system. 
 pka of the drug and dissolution rate of solid from its 
dosage forms. 
Important properties pf the parenteral 
suspensions for the formulation development: 
Suspension ingredients: 
 It contains both active ingredients and excipients. 
 The therapeutic effect of the active ingredient must not 
interfere. 
 The sterilization and stability during the shelf-life 
should be maintained. 
 The excipients used in parenteral preparations should 
be physically and chemically compatible with active 
ingredients. 
 The preparations must be non-pyrogenic, non-toxic, 
non-haemolytic and non-irritating. 
 The parenteral preparations must be effective at low 
concentration. 
Typical excipients used in parenteral suspensions: 
 Flocculating or Suspending Agents. 
 Wetting agents. 
 Solvent Systems. 
 Preservatives. 
 Anti-oxidants. 
 Chelating Agents. 
 Buffering Agents 
 Flocculating or suspending agents:[3] 
 In these processes three techniques are used to formulate a 
suspension 
(a) Controlled flocculation 
(b) Structured Vehicle 
(c) Combination of (a) and (b) 
 Surfactants: 
These flocculating agents are used to form flocs in a 
controlled manner that settles rapidly but  re-disperses 
easily upon agitation. The hydrophilic colloids affects the 
repulsive forces also provide the mechanical barrier of the 
particles. 
Examples: Lecithin, Polysorbate 20, Pluronic F-68, 
 Hydrophilic colloids: 
These are used as structured vehicles, these form 
pseudoplastic or plastic systems with some degree of 
thixotropy. It has high viscosity and poor syringeability. 
Examples: Sodium Carboxy Methyl Cellulose, Acacia, 
Gelatine, Methyl Cellulose, Polyvinyl pyrrolidine. 
 Electrolytes: 
These reduce the repulsion between the particles and allow 
the flocs to form and the surface charge of the particles are 
influenced. 
Examples: Potassium / sodium chloride, Potassium / sodium 
citrate, Potassium / sodium acetate. 
 Wetting agents:[3,10] 
The contact angle between the surface of the particles and 
the wetting liquid is reduced. Hydrophilic powders are 
suspended in aqueous system which are useful. The 
hydrophilic lipophilic balance value is in the range of 7-9 
should only be selected for the process of wetting agents. The 
concentration of the surfactants should vary from 0.05%- 
0.5% based on the solid contents of the suspensions. The 
excessive amounts may cause caking or provide an 
undesirable taste or odour to the product. 
Examples: Non-aqueous solvents (Glycerine, alcohol, and 
Propylene glycol). Non-ionic surfactants (Polysorbate 
80,Polysorbate 20, Polysorbate 40). 
 Solvent system:[3,11] 
These are classified into aqueous or non-aqueous vehicles. 
The typical solvent systems depends on solubility, stability, 
and release the characteristics of the drug. Non-Aqueous 
vehicles include both water miscible and water immiscible 
vehicles. The nonaqueous agents are used as co-solvents for 
the process of water for injection. The water miscible co-
solvents can lead to different side effects. 
Examples: Intramuscular injection of propylene glycol – 
water, Ethyl alcohol – water and Polyethylene glycol are 
found to cause muscle damage and release of creatinine 
kinase from isolated rat skeletal muscle. 
 Organic co – solvents are less myotoxic than propylene 
glycol and ethanol. 
Water miscible examples: Ethanol, Glycerine, Propylene 
glycol, N-(Beta-hydroxyethyl)-lactamide. 
Water immiscible included fixed oils like Sesame oil, Peanut 
oil, Castor oil, Almond oil, Sunflower oil, Iodinated Poppy 
seed oil. 
 Tonicity agents:[3,12] 
Isotonicity of the parenteral preparations for subcutaneous 
or intramuscular administration is used to prevent pain, 
irritation, and tissue damage at the area of administration. 
Dextrose and various electrolytes are parenteral 
suspensions. The aqueous solutions of Tonicity Agents are 
used in parenteral suspensions. 
Examples: Dextrose, Sodium chloride. 
 Preservatives:[3,13] 
Preservatives should be added to the formulations which are 
packed in single dose and does not have bactericidal or 
bacteriostatic property and which promotes the growth. The 
growth promoting is conducted for the determination of 
microbiological properties which are preservative free 
formulations. 
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The parenteral products which are used in multiple doses 
are used to protect the products from the accidental 
microbial contamination during clinical usage and which 
maintain the stability. 
Examples: Benzyl alcohol (0.9% - 1.5%), Methyl Paraben 
(0.18% - 0.2%), Propyl Paraben (0.02%), Benzalkonium 
Chloride (0.01% - 0.02%), Thimerosal (0.001% - 0.01%) 
The chemically reactive nature of preservatives, stability and 
compatibility of preservatives should be used in the final 
formulations. Parabens decreases in stability with increase 
in ph. concentration which are used in parenteral 
formulations. 
 Antioxidants or chelating agents:[3,14] 
These are added in the formulations to minimize its 
degradation which result their over oxidation potential or by 
terminating the propagation in the free radical oxidation 
mechanism. These are used in combination with a chelating 
agents or other anti- oxidants and found to act as synergists 
and increase the effectiveness of anti – oxidants that block 
oxidative reaction. 
Examples: Water soluble - ascorbic acid-0.02 - 0.1%, sodium 
bisulphite -0.1 – 0.15%, sodium metabisulfite-0.1 – 0.15%, 
thiourea- 0.005%. 
Auto-oxidation is defined as oxidative degradation by 
molecular oxygen. The manufacturing process should be 
avoided in the case of exposure of active ingredients to 
oxygen. 
 Buffering agents: 
The maintained pH. should be altered in the formulation the 
pH of the product occurs during the storage because of: 
 The reactions take in the place in the product are 
degraded. 
 The components of the product are interacted. 
 To control the pH of the formulation buffers are 
commonly used in the parenteral formulations. 
The temperature is high and it should facilitate the faster 
primary drug and it is non-volatile which determines the 
stability. Acetate buffer is not used due to its volatile nature 
and it is lost due to lyophilization. The pH decreased is of 
about 4 units. 
Examples: Citric acid, Sodium citrate. 
Manufacturing of parenteral preparations:[3] 
Two basic methods are used in manufacturing of parenteral 
preparations: 
1.The sterile powders and vehicles are aseptically combined. 
This method involves dispersing the sterile products 
aseptically , milled active ingredients and milling the 
resulting suspensions as required into the suitable 
containers. Example: Penicillin G. 
2.The sterile products are combined by crystal formulation. 
These are solubilized in suitable solvent systems, which are 
sterile counter systems  which are added to the active 
ingredients and are removed aseptically and the resulting 
suspension is milled. Examples: Testosterone, Insulin. 
Official examples of parenteral suspensions: 
 (1) Sterile ampicillin suspension USP’95 dispense as powder 
which is to be reconstituted at time of administration. 
(2) Sterile Aurothiglucose suspension USP’95 – vegetable oil 
suspension. 
(3) Tetanus toxoid adsorbed USP’95, IP’96 – aq. Suspension. 
(4) Betamethasone acetate suspension USP’96 aq. 
Suspension. 
(5) Insulin Zinc suspension USP’95, IP’96 aq. Suspension. 
(6) Procaine penicillin suspension IP’96. 
CONCLUSION: 
Suspension is a better choice of drug dosage form due to its 
fast onset of action and its bioavailability over the other 
dosage forms. As the other dosage forms facing the problem 
of first pass metabolism and other drug stabilities, in respect 
to above qualities suspension is a good choice of drug. Many 
pharmaceutical industries are volunteer to manufacture 
parenteral suspension dosage forms due to its worthwhile 
over other standard dosage form. 
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